team up

Rigel Pharmaceuticals Finalizes Pact with Eli Lilly for RIPK1 Inhibitor

April 8, 2021

Rigel Pharmaceuticals and Eli Lilly have finalized an agreement to jointly develop Rigel’s RIPK1 inhibitor, R552, for a variety of autoimmune and inflammatory diseases.

RIPK1 (receptor-interacting serine/threonine-protein kinase 1) is an enzyme that regulates immune cells and RIPK1 inhibitors are being investigated as potential oral treatments for a range of degenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson’s disease.

Under the agreement, Rigel received an upfront payment of $125 million, with the potential for an additional $330 million in milestone payments for noncentral nervous system (CNS) disease products, and $255 million in milestone payments for CNS disease products.

View today's stories